RNA-sequencing of WFS1-deficient pancreatic islets

Marilin Ivask1, Alison Hugill2 & Sulev Köks1

1 Department of Pathophysiology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia
2 Mammalian Genetics Unit, Medical Research Council, Harwell, Oxfordshire, United Kingdom

Keywords
Insulin, RNA-sequencing, Trpm5, Wfs1.

Abstract
Wolfram syndrome, an autosomal recessive disorder characterized by juvenile-onset diabetes mellitus and optic atrophy, is caused by mutations in the WFS1 gene. WFS1 encodes an endoplasmic reticulum resident transmembrane protein. The Wfs1-null mice exhibit progressive insulin deficiency and diabetes. The aim of this study was to describe the insulin secretion and transcriptome of pancreatic islets in WFS1-deficient mice. WFS1-deficient (Wfs1KO) mice had considerably less pancreatic islets than heterozygous (Wfs1HZ) or wild-type (WT) mice. Wfs1KO pancreatic islets secreted less insulin after incubation in 2 and 10 mmol/L glucose and with tolbutamide solution compared to WT and Wfs1HZ islets, but not after stimulation with 20 mmol/L glucose. Differences in proinsulin amount were not statistically significant although there was a trend that Wfs1KO had an increased level of proinsulin. After incubation in 2 mmol/L glucose solution the proinsulin/insulin ratio in Wfs1KO was significantly higher than that of WT and Wfs1HZ. RNA-seq from pancreatic islets found melastatin-related transient receptor potential subfamily member 5 protein gene (Trpm5) to be downregulated in WFS1-deficient mice. Functional annotation of RNA sequencing results showed that WFS1 deficiency influenced significantly the pathways related to tissue morphology, endocrine system development and function, molecular transport network.

Introduction
Wolfram syndrome (WS, OMIM 222300) is a rare autosomal recessive neurodegenerative disorder caused by mutations in the wolframin gene (WFS1). The main symptoms of the disease are juvenile-onset diabetes mellitus, progressive optic atrophy, diabetes insipidus and deafness (Barrett and Bundey 1997; Inoue et al. 1998; Strom et al. 1998). Nonautoimmune degeneration of pancreatic β-cells is common for WS patients (Karaski et al. 1989). In patients with WS high levels of endoplasmic reticulum (ER) stress and pancreatic β-cell death may be associated with impaired β-cell function as in the case of type 2 diabetes (T2D) (Fonseca et al. 2005). Genetic studies have also shown a link between the risk of developing T2D and WFS1 (Minton et al. 2002; Sandhu et al. 2007; Florez et al. 2008; Franks et al. 2008; van Hoek et al. 2008; Cheurfa et al. 2011).

WFS1 is a 100 kDa glycoprotein composed of 890 amino acids and has nine transmembrane segments. Inside the cell WFS1 localizes in the ER (Takeda et al. 2001; Hofmann et al. 2003; Philbrook et al. 2005). Its location in the ER suggests that WFS1 could participate in membrane trafficking, processing proteins and/or regul-
loration of the Ca\(^{2+}\) homeostasis in the ER (Takeda et al. 2001). WFS1 itself may be a Ca\(^{2+}\)-channel in the ER or its regulator (Osman et al. 2003). WFS1 is expressed at highest levels in brain, heart and pancreatic \(\beta\)-cells (Inoue et al. 1998; Strom et al. 1998; Hofmann et al. 2003; Ishihara et al. 2004).

Wfs1-mutant mice have been generated in several laboratories (Ishihara et al. 2004; Riggs et al. 2005; Luuk et al. 2008; Koks et al. 2009). One model is a knock-out of the second exon in \(129Sv \times B6\) F2 background and the resulting WFS1 protein lacks first 183 amino acids and NH\(_2\)-terminus (Ishihara et al. 2004). Riggs et al. (2005) generated a pancreatic islet specific conditional Wfs1 mouse model disrupting exon 8. The WFS1-deficient mice (Wfs1\(^{tm1Koks}\)) used in current study have also the exon 8 disrupted resulting in the deletion of amino acids 360–890 (Luuk et al. 2008; Koks et al. 2009).

Mice with a loss of function of the Wfs1 gene exhibit \(\beta\)-cell loss, which may result from high levels of ER stress, cell cycle dysfunction, and apoptosis (Fonseca et al. 2005; Riggs et al. 2005; Takei et al. 2006; Yamada et al. 2006). Insulin secretion from isolated islets of mice with a disrupted Wfs1 gene has been shown to be impaired (Ishihara et al. 2004). However, there is no more detailed analysis of insulin secretion in Wfs1-mutant mice.

RNA-sequencing (RNA-seq) has become a great tool for transcriptomic studies without the need of previous knowledge of the targets, allowing identifying novel transcripts and gene expression changes due to some disease (Mortazavi et al. 2008). There have been studies regarding pancreatic islets' transcriptome and differential gene expression caused by diabetes (Eizirik et al. 2012; Ku et al. 2012; Moran et al. 2012). However, the transcriptional changes in the islets induced by the deletion of WFS1 are not known.

The aim of this study was to perform analysis of insulin secretion and proinsulin content in isolated pancreatic islets of WFS1-deficient mice (Wfs1\(^{tm1Koks}\)) (Luuk et al. 2008; Koks et al. 2009). The transcriptome of islets was analyzed using RNA-seq to describe transcriptional changes in pancreatic islets associated with Wfs1 deficiency and potentially related to the changes in insulin secretion.

**Methods**

**Animals**

The animal experiments described in this study were performed with permission from Estonian National Board of Animal Experiments (No. 71, April 8th, 2011) and in accordance with the European Communities Directive (86/609/EEC).

Generation of Wfs1 mutant (Wfs1KO, Wfs1\(^{tm1Koks}\)) mice has been described elsewhere (Luuk et al. 2008; Koks et al. 2009). Briefly, most of exon 8 was replaced with a LacZ cassette resulting in the deletion of amino acids 360–890 in the WFS1 protein. The expressed truncated protein is a fusion between WFS1 residues 1–359 (N-terminal part) and LacZ lacking at least seven of the nine transmembrane domains and the C-terminal portion of endogenous WFS1 protein (Luuk et al. 2008; Koks et al. 2009). In the study 3 genotypes of mice were used: wild-type (WT), heterozygotes for Wfs1 mutation (Wfs1HZ) and homozygous for Wfs1KO. All studies were performed on male F2 hybrids (129S6/SvEvTac \(\times\) C57BL/6) and mice were 5–6-month-old at the time of the experiment. Mice were housed in groups of 6–8 at 20 ± 2°C under 12-h/12-h light/dark cycle with free access to food and water.

**Isolation of pancreatic islets**

Pancreatic islets were isolated as previously described (Shimomura et al. 2009) from six mice in each genotype. Briefly, mice were executed by cervical dislocation and the islets isolated by collagenase Type XI digestion (Sigma-Aldrich, St. Louis, MO, USA, final concentration 1 mg/mL). The inflated pancreas was dissected out and incubated in a 37°C water bath for 13 min. Only pancreata inflated 100% were used. The tissue was washed twice with 0.2% BSA (Sigma) and HBSS (Sigma) solution. The islets were handpicked under stereomicroscope in 0.2% BSA and HBSS solution. Finally, the islets were picked into high glucose (4.5 g/L) DMEM/Ham’s F12 media (PAA/GE Healthcare Life Sciences, Chicago, IL, USA), containing 10% FBS (Gibco/Thermo Fisher Scientific Inc., Waltham, MA, USA), 100 U/mL penicillin and 100 μg/mL streptomycin (Gibco) and 20 mmol/L L-glutamine (Invitrogen/Thermo Fisher Scientific Inc., Waltham, MA, USA). Islets were incubated overnight at 37°C before insulin secretion assay. During the picking the number of islets was also counted manually.

**Insulin secretion assay**

Islets were incubated for 1 h at 37°C and 5% CO\(_2\) in 0.2% BSA and Krebs-Ringer solution (KRBH, 140 mmol/L NaCl, 0.5 mmol/L Na\(_2\)HPO\(_4\), 2 mmol/L NaHCO\(_3\), 3.6 mmol/L KCl, 0.5 mmol/L MgSO\(_4\), 2.6 mmol/L CaCl\(_2\)-2H\(_2\)O, 5 mmol/L HEPES, pH 7.4) containing 2 mmol/L glucose. Then, islets were incubated for 1 h at 37°C and 5% CO\(_2\) in selected assay solution (KRBH and 2 mmol/L, 10 mmol/L or 20 mmol/L glucose or 200 μmol/L tolbutamide and 2 mmol/L glucose). Tolbutamide (Sigma) was first dissolved in 0.2% DMSO (Sigma) with final concentration of 200 μmol/L. Each assay media group contained 5 islets and
was in duplicate per genotype. After incubation the supernatant was collected and stored at −20°C until ELISA analysis. To determine total insulin content, insulin was extracted from the same islets using 95:5 ethanolacetic acid solution (Shimomura et al. 2009). Insulin concentration was determined with Ultra Sensitive Mouse Insulin ELISA Kit (Crystal Chem Inc., Downers Grove, IL, USA). Insulin amount was determined separately from secretion and islet content samples. To reduce the effect of variation in islet size on insulin secretion, the secreted amount of insulin was normalized to the content of insulin (secreted insulin divided by insulin content).

Proinsulin concentration was measured from islet content samples with Mouse Proinsulin ELISA Kit (Wuhan ELab Science Co., Ltd., Wuhan, China). Proinsulin was also determined from secretion samples, but the results were too low and did not reach the detection range. Differences in the amount of proinsulin were normalized to the number of islets used in each well. To compare proinsulin/insulin ratio between genotypes the proinsulin concentration was divided with corresponding normalized insulin.

**Transcriptome analysis**

RNA-sequencing was used for transcriptome analysis. Pancreatic islets from 4 animals were used in each genotype group. Total RNA was isolated from islets using the RNeasy Mini Kit (Qiagen Inc., Valencia, CA, USA) according to manufacturer’s protocol and cDNA for sequencing was synthesized using Ovation RNA-Seq System V2 (NuGEN Technologies Inc., San Carlos, CA, USA), 10 ng of total RNA was used. SOLiD DNA Fragment library kit (cDNA input 2 μg) was used to generate libraries and quality was controlled with the Agilent Bioanalyzer 2100 (Agilent Technologies Inc., Santa Clara, CA, USA) before sequencing. The libraries were marked with different barcodes and pooled together for the template preparation with automated SOLiD EZ Bead E80 System and its consumables (Life Technologies/Thermo Fisher Scientific Inc., Waltham, MA, USA). The SOLiD 5500xl System and paired end (75 bp forward and 35 bp reverse) chemistry (Life Technologies) were used for sequencing. Samples from each animal were sequenced and analyzed separately.

All the raw sequences are deposited in the sequence read archive (http://trace.ncbi.nlm.nih.gov/Traces/sra/) under the accession number GSE65929.

**Quantitative real-time PCR validation**

The confirmatory quantitative real-time PCR (RT-PCR) was performed using TaqMan gene expression assays and chemistry (Life Technologies). Samples were treated with TURBO DNA-free kit (Ambion/Thermo Fisher Scientific Inc., Waltham, MA, USA), according to the manufacturer’s instructions to remove contaminating genomic DNA. Total RNA of 10 ng from each sample was subjected to cDNA synthesis using High Capacity cDNA Reverse Transcription Kit (Life Technologies) following the manufacturer’s protocol. The expression of Glipr2 (glioma pathogenesis-related protein 2, Mm01341451_m1, FAM), Trpm5 (Mm01129032_m1, FAM), Gad1 (glutamate decarboxylase 1, Mm00725661_s1, FAM), MaoB (monoamine oxidase B, Mm00555412_m1, FAM), ApoE (apolipoprotein E, Mm01307193_g1, FAM) was analyzed using the ABI Prism 7900 HT Sequence Detection System (Life Technologies). The same samples were analyzed two times, but three times for Trpm5.

**Statistical analysis**

Islet and insulin secretion data are presented as mean ± SEM. Data were analyzed using either one-way or two-way ANOVA, followed by Tukey post test. A P value of <0.05 was considered statistically significant (P < 0.05). The statistical analysis was performed using GraphPad Prism 5 software (GraphPad Software Inc., La Jolla, CA, USA).

Data from RT-PCR are presented as mean of 2−ΔCt ± SEM calculated in relation to the TaqMan Endogenous Control assay for Hprt (hypoxanthine phosphoribosyltransferase, Mm00446968_m1, VIC, primer limited). Data for studied genes were analyzed by one-way ANOVA and Tukey post hoc test using GraphPad Prism 5 software (GraphPad Software Inc.) and a P value <0.05 was considered significant.

For RNA-seq data analysis sequencing reads were mapped to the mouse genome (version mm10) using the genomic analysis software LifeScope (Life Technologies). Data were further analyzed for the differential expression with the edgeR package implemented in the statistical software R (http://www.r-project.org/).

**Functional annotation of transcriptome**

Ingenuity Pathway Analysis (IPA, Ingenuity Systems, http://www.ingenuity.com) was used to define the functional networks of differentially expressed genes. The uploaded dataset contained gene identifiers, corresponding false discovery rate (FDR) and fold change values.

As standard workflow in IPA each gene identifier was mapped to its corresponding gene object in the Ingenuity Pathways Knowledge Base to generate the list of focus genes. Based on the connectivity of these focus genes the IPA software generates networks and calculates a significance score for each network. The score is generated from the P value and is displayed as the negative logarithm of P.
that $P$ value. This score indicates the likelihood that the assembly of a set of focus genes in a network could be explained by random chance alone. A score of 2 indicates that there is a 1 in 100 chance that the focus genes are together in a network due to random chance.

Functional analysis was performed on the entire dataset and filtered to get only FDR corrected significant genes. Statistical significance filtering was used to increase the focus and specificity of analysis.

**Results**

**The number of pancreatic islets**

The number of pancreatic islets was manually counted during handpicking. The difference in number of isolated pancreatic islets between genotypes was statistically highly significant (WT 303 ± 7.3, Wfs1HZ 176 ± 14 and Wfs1KO 80 ± 7.5, $P < 0.001$) (Fig. 1). Wfs1KO animals had remarkably less pancreatic islets than WT or Wfs1HZ animals indicating a genotypic effect.

**Insulin secretion**

The basal insulin secretion after incubation in 2 mmol/L glucose (Fig. 2) for Wfs1KO islets (0.051 ± 0.016) was reduced compared to WT (0.148 ± 0.014) and Wfs1HZ (0.143 ± 0.027) islets ($P < 0.001$).

When islets were stimulated with 10 mmol/L glucose (Fig. 2) solution, the difference in secreted insulin between WT (0.201 ± 0.009) and Wfs1KO (0.146 ± 0.020) was significant ($P < 0.05$), the difference between Wfs1HZ (0.212 ± 0.018) and Wfs1KO was highly significant ($P < 0.01$).

**Proinsulin amount and proinsulin/insulin ratio**

The average proinsulin amount per islet (Fig. 3) was not significantly different between the genotypes (2 mmol/L glucose: WT 4.636 ± 0.739 pmol/L, Wfs1HZ 5.047 ± 0.969 pmol/L and Wfs1KO 7.958 ± 1.59 pmol/L; 10 mmol/L glucose: WT 4.296 ± 0.805 pmol/L, Wfs1HZ 4.309 ± 0.558 pmol/L and Wfs1KO 5.489 ± 1.56 pmol/L; 20 mmol/L glucose: WT 4.703 ± 0.864 pmol/L, Wfs1HZ 4.333 ± 0.700 pmol/L and Wfs1KO 6.199 ± 1.53 pmol/L; tolbutamide: WT 5.120 ± 1.08 pmol/L, Wfs1HZ 4.055 ± 0.852 pmol/L and Wfs1KO 5.202 ± 0.950 pmol/L, $P > 0.05$).

When islets were incubated in 2 mmol/L glucose solution, there was no significant difference in proinsulin/insulin ratio between WT (0.256 ± 0.065) and Wfs1HZ (0.632 ± 0.150, $P > 0.05$). However, the much higher Wfs1KO proinsulin/insulin ratio (6.345 ± 0.680) was extremely different from ratios of WT and Wfs1HZ genotypes ($P < 0.001$) (Fig. 4A). After treating islets with other glucose doses (10 mmol/L glucose: WT 0.148 ± 0.023, Wfs1HZ 0.143 ± 0.025 and Wfs1KO 0.321 ± 0.140; 20 mmol/L glucose: WT 0.165 ± 0.016, Wfs1HZ 0.156 ± 0.008 and Wfs1KO 0.204 ± 0.042) and tolbutamide (WT 0.247 ± 0.072, Wfs1HZ 0.175 ± 0.0174 and Wfs1KO 0.650 ± 0.235) there were no significant difference in proinsulin/insulin ratio between the genotypes ($P > 0.05$) (Fig. 4B). However, the ratio of proinsulin/insulin was constantly higher in Wfs1KO mice indicating a larger amount of unprocessed insulin in the islets.

**Transcriptome analysis**

The number of reads per sample varied from 27 million to 72 million. The number of transcripts mapped to
mouse genome was 22613 between Wfs1KO and WT, 22619 between Wfs1KO and Wfs1HZ and 22591 between Wfs1HZ and WT. EdgeR exact test of RNA-seq data revealed 20 genes with FDR under 0.05 (Table 1A), between Wfs1KO and Wfs1HZ were 13 genes with FDR < 0.05 (Table 1B). With FDR < 0.2 there were additional 29 genes different between Wfs1KO and WT (data not shown), 7 genes between Wfs1KO and Wfs1HZ (data not shown) and one gene between Wfs1HZ and WT (Dpep1, logFC = 3.507, logCPM = 2.759, P = 7.21E-06, FDR = 0.173). The most
significantly downregulated gene associated with insulin secretion and diabetes in WFS1-deficient islets following Wfs1 was melastatin-related transient receptor potential subfamily member 5 (Trpm5).

Various ER stress markers from RNA-seq (Wfs1KO islets compared to WT islets) are presented in Table 2. The FDR and log ratio values of these ER stress markers were not significant. Ingenuity functional pathway analysis software was used for more general functional annotation of the differential gene sets. Network analysis of the genes with lowest P values (filter set to P < 0.05 after FDR correction) of Wfs1KO compared to WT revealed significant enrichment of tissue morphology, endocrine system development and function, molecular transport network (score 33, Fig. 5). Analysis of Wfs1KO compared to Wfs1HZ revealed a network associated with cellular development, cellular growth and proliferation, hepatic system development and function (score 28, Fig. 6).

**Quantitative real-time PCR confirmation**

To determine whether similar changes in gene expression could be observed with RT-PCR analysis the expression of Glipr2, Trpm5, Gad1, MaoB, ApoE genes and the values of three genotypes were compared with one-way ANOVA followed by Tukey post hoc test (Fig. 7). ApoE and Glipr2 were upregulated according to RNA-seq, but RT-PCR did not confirm it statistically, although there was a trend that ApoE and Glipr2 are upregulated in Wfs1KO islets. The downregulation of Gad1, MaoB, and Trpm5 was confirmed in Wfs1KO islets (P < 0.05).

**Discussion**

Previous studies have shown that WFS1-deficient (Wfs1tm1Koks) mice have disturbed blood glucose regulation and their plasma insulin level is lower, but plasma proinsulin level higher (Luuk et al. 2009; Noormets et al. 2011; Terasmaa et al. 2011). In this study, the difference in transcriptome and insulin secretion from isolated pancreatic islets of WFS1-deficient (Wfs1tm1Koks) mice were studied, also differences in proinsulin levels and proinsulin/insulin ratio were detected.

WFS1-deficient mice had considerably fewer pancreatic islets than heterozygous or wild-type mice during isolation. This has also been noticed in previous studies (Ishihara et al. 2004; Riggs et al. 2005). The immunohistochemistry of the same WFS1-deficient (Wfs1tm1Koks) mouse line has been done by Terasmaa et al. (2011) showing that the islets of WFS1-deficient mice also seem to be smaller. β-cells with defective WFS1 are more prone to ER stress induced apoptosis (Ishihara et al. 2004; Philbrook et al. 2005; Riggs et al. 2005; Yamada et al. 2006) which could cause the reduced number of pancreatic islets in WFS1-deficient mice (Riggs et al. 2005).

According to current RNA-seq results the down- or upregulation of various ER stress markers was not statically significant, although it has been shown that the levels of ER stress markers from all three UPR pathways are increased in the absence of WFS1 (Yamada et al. 2006; Fonseca et al. 2010). WFS1 is shown to downregulate ATF6α and its
Table 1. RNA-seq results of pancreatic islets showing genes with FDR < 0.05.

| Gene               | Log ratio | P value     | False discovery rate (q-value) | Entrez gene name                                      |
|--------------------|-----------|-------------|-------------------------------|-------------------------------------------------------|
| **(A). Wfs1KO compared to WT** |           |             |                               |                                                       |
| Wfs1               | −2.663    | 2.18E-12    | 5.24E-08                      | Wolfram syndrome 1 (wolframin)                        |
| Gilp2              | 3.139     | 1.42E-09    | 1.71E-05                      | GLI pathogenesis-related 2                             |
| Trpm5              | −2.422    | 4.05E-09    | 3.25E-05                      | Transient receptor potential cation channel, subfamily M, member 5 |
| Gad1               | −2.671    | 9.94E-08    | 5.98E-04                      | Glutamate deacarbonylase 1 (brain, 67kDa)              |
| Spock1             | −1.801    | 8.71E-07    | 4.19E-03                      | Sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 1 |
| Sprr1a             | 2.623     | 1.36E-06    | 5.44E-03                      | Small proline-rich protein 1A                         |
| Bcat1              | 1.821     | 1.67E-06    | 5.75E-03                      | Branched chain amino-acid transaminase 1, cytosolic   |
| Csf3               | 2.332     | 2.03E-06    | 6.12E-03                      | Colony-stimulating factor 3 (granulocyte)             |
| Nrxn1              | −1.404    | 5.14E-06    | 1.38E-02                      | Neurexin 1                                             |
| Prss23             | 1.769     | 7.19E-06    | 1.62E-02                      | Protease, serine, 23                                  |
| Aw551984           | −1.551    | 7.40E-06    | 1.62E-02                      | Expressed sequence AW551984                          |
| Cxcl9              | 3.394     | 8.28E-06    | 1.66E-02                      | Chemokine (C-X-C motif) ligand 9                      |
| MaoB               | 1.867     | 1.02E-06    | 1.89E-02                      | Monoamine oxidase B                                   |
| Kcn3               | 4.122     | 1.17E-05    | 2.02E-02                      | Potassium voltage-gated channel, delayed-rectifier, subfamily S, member 3 |
| Zfp36              | 1.709     | 1.71E-05    | 2.74E-02                      | ZFP36 ring finger protein                             |
| Egr1               | 1.392     | 2.65E-05    | 3.97E-02                      | Early growth response 1                               |
| ApoE               | 1.712     | 2.91E-05    | 3.97E-02                      | Apolipoprotein E                                      |
| Itgb3              | 1.701     | 2.97E-05    | 3.97E-02                      | Integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) |
| Ccdc85B            | 1.566     | 3.38E-05    | 4.07E-02                      | Coiled-coil domain containing 85B                    |
| Npas4              | −1.767    | 3.38E-05    | 4.07E-02                      | Cyclin M1                                              |
| **(B). Wfs1KO compared to Wfs1HZ** |           |             |                               |                                                       |
| Trpm5              | −3.292    | 2.04E-12    | 4.92E-08                      | Transient receptor potential cation channel, subfamily M, member 5 |
| Gad1               | −2.834    | 6.40E-08    | 7.70E-04                      | Glutamate deacarbonylase 1 (brain, 67kDa)              |
| Bcat1              | 1.871     | 1.02E-05    | 1.89E-02                      | Branched chain amino-acid transaminase 1, cytosolic   |
| Serpina7           | 2.855     | 4.68E-07    | 2.82E-03                      | Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 7 |
| Dpyd               | −1.746    | 2.34E-06    | 9.38E-03                      | Dihydropyrimidine dehydrogenase                       |
| Spock1             | −1.758    | 3.01E-06    | 1.01E-02                      | Sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 1 |
| Npas4              | −3.008    | 3.35E-06    | 1.01E-02                      | Neuronal PAS domain protein 4                         |
| Cxcl9              | 3.563     | 4.36E-06    | 1.14E-02                      | Chemokine (C-X-C motif) ligand 9                      |
| Sprr1a             | 2.328     | 4.73E-06    | 1.14E-02                      | Small proline-rich protein 1A                         |
| Insr               | −2.356    | 7.32E-06    | 1.49E-02                      | Insulin receptor-related receptor                     |
| Cpb2               | 2.129     | 7.44E-06    | 1.49E-02                      | Carboxypeptidase B2 (plasma)                          |
| Bhlha15            | 1.759     | 2.38E-05    | 4.40E-02                      | Basic helix-loop-helix family, member a15             |

FDR, false discovery rate; Wfs1HZ, pancreatic islets of Wfs1 heterozygous mice; Wfs1KO; pancreatic islets of Wfs1 deficient mice.

Table 2. RNA-seq results of ER stress markers (Wfs1KO compared to WT islets).

| Gene    | Log ratio | P value     | False discovery rate (q-value) | Entrez gene name                                      |
|---------|-----------|-------------|-------------------------------|-------------------------------------------------------|
| Atf6    | 0.535     | 0.095       | 1                             | Activating transcription factor 6                      |
| Err1 (Ire1α) | −0.211    | 0.795       | 1                             | Endoplasmic reticulum to nucleus signaling 1 (inositol-requiring enzyme 1) |
| Xbp1    | −0.017    | 0.697       | 1                             | X-box-binding protein 1                                |
| Elf2ak3 (Perk) | −0.214    | 0.409       | 1                             | Eukaryotic translation initiation factor 2 (eukaryotic translation initiation factor 3 (protein kinase R-like endoplasmic reticulum kinase)) |
| Atf4    | 0.193     | 0.633       | 1                             | Activating transcription factor 4                      |
| Ddit3 (Chop) | 0.215     | 0.595       | 1                             | DNA-damage inducible transcript 3 (C/EBP homologous protein) |
| Hspa5 (Bip) | 0.347     | 0.176       | 1                             | Heat-shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) |

ER, endoplasmic reticulum; WT, wild-type.
downstream targets (Fonseca et al. 2010). It has been shown that in the pancreatic β-cells of WFS1-deficient mice the expression of GRP78 and GRP94 has increased, also levels of spliced XPB1 (Yamada et al. 2006). The possible explanation may be that gene expression might not always correspond to protein level and most of the ER stress marker studies have been done in cell lines and also the mouse line (Wfs1<sup>tm1Koks</sup>) used in this study that is not a complete knock-out of Wfs1. A truncated WFS1 protein lacking amino acids 360–890 (C-terminal portion) and at least seven of the nine transmembrane domains is expressed resulting in defective function (Luuk et al. 2008; Koks et al. 2009).

WFS1-deficient pancreatic islets secreted less insulin after incubation in 2 mmol/L and 10 mmol/L glucose solution compared to WT and Wfs1HZ islets. Surprisingly the overall secretion after stimulation was not as high as expected and there was no statistically significant difference after stimulation with 20 mmol/L glucose, however, there was a trend that Wfs1KO islets secreted less insulin. The rise of insulin secreted after stimulation with 10 mmol/L compared to 20 mmol/L glucose was greater for Wfs1KO islets while the amount of secreted insulin stayed more or less at the same level for WT and Wfs1HZ islets, which was not expected and could not be explained. In general this result is in accordance with previous studies made by Ishihara et al. (2004) and Riggs et al. (2005), although Ishihara et al. (2004) could not see a difference in insulin secretion after incubation in 2.5 mmol/L glucose (Ishihara et al. 2004; Riggs et al. 2005). This variation could be due to differences in Wfs1 mouse models as current WFS1-deficient mice have a disrupted exon 8 (Koks et al. 2009) and the other model is a complete knock-out of exon 2 (Ishihara et al. 2004). The disruption of exon 8 leads to a dysfunctional protein mimicking more accurately Wolfram syndrome as most mutations in the WFS1 gene occur in exon 8 (Cryns et al. 2003). Wfs1KO islets also showed a significant reduction in the amount of insulin secreted in response to sulfonylurea tolbutamide. Tolbutamide forces β-cells to secrete insulin independent of glucose metabolism by closing the ATP-sensitive K<sup>+</sup> (K<sub>ATP</sub>) channels directly which results
in membrane depolarization, Ca\(^{2+}\) influx and insulin release (Ashcroft and Rorsman 1989). WFS1 may therefore exert its effect on insulin secretion at or downstream of the K\(_{ATP}\) channel.

In vivo studies with WFS1-deficient mice have shown that Wfs1KO mice have lower plasma insulin level than WT mice (Noormets et al. 2011; Terasmaa et al. 2011). In this study, there was no difference in insulin secretion between WT and Wfs1HZ, which is in accordance with in vivo results by Terasmaa et al. (2011). The lower insulin amount seen in Wfs1KO mice was primarily due to decreased insulin secretion, because the insulin content in pancreatic islets did not significantly differ between genotypes. These and previous results indicate a defect in insulin secretion in WFS1-deficient pancreatic \(\beta\)-cells (Ishihara et al. 2004; Hatanaka et al. 2011).

Hatanaka et al. (2011) showed that WFS1 localized in \(\beta\)-cells and also to secretory granules and WFS1 deficiency caused changes in the intragranular pH, which in turn caused defects in proinsulin processing. Therefore, the level of circulating proinsulin is higher in WFS1-deficient mice (Noormets et al. 2011). In this study, there were no significant differences in proinsulin amount per pancreatic islet between genotypes, although there was a trend that Wfs1KO had an increased level of proinsulin. The Wfs1KO proinsulin/insulin ratio was significantly higher compared to WT and Wfs1HZ only after incubation in 2 mmol/L glucose solution. There was also a trend that Wfs1KO proinsulin/insulin ratio was increased after stimulation with other solutions. Higher proinsulin/insulin ratio is associated with T2D (Mykkanen et al. 1997) indicating that WFS1-deficient mice have a diabetic phenotype. The current results also indicate that there may be a problem with conversion of proinsulin to insulin and release of insulin from granules. This is in accordance with previous studies by Hatanaka et al. (2011).

According to functional annotation of RNA-seq results genes with highest expressional changes due to WFS1 deficiency belong to the "tissue morphology, endocrine system development and function, molecular transport"
A functional network. Although only four samples of each genotype were sequenced, RNA sequencing revealed that melastatin-related transient receptor potential subfamily member 5 (Trpm5) is downregulated in that pathway of Wfs1KO pancreatic islets. TRPM5 (melastatin-related transient receptor potential subfamily member 5 protein) is expressed in the pancreatic islets of Langerhans and regulates Ca²⁺ oscillations contributing to insulin secretion (Brixel et al. 2010; Colson et al. 2010). Colson et al. (2010) showed that the action potentials of Trpm5-mutant islet cells did not change, but the frequency of oscillations did. Trpm5-mutant islet cells maintain slow oscillations but lack of fast oscillations (Colson et al. 2010).

TRPM5 is shown to regulate glucose-stimulated insulin secretion as Trpm5 knock-out mice have impaired glucose...
tolerance. They have prolonged elevation of blood glucose levels, suggesting disturbances in insulin secretion (Brixel et al. 2010; Colsoul et al. 2010). TRPM5 forms a functional calcium-activated nonselective cation channel conducting mainly Na$^+$ and K$^+$ ions without significant permeation to Ca$^{2+}$. Its activation presumably causes membrane depolarization downstream of the closure of $K_{ATP}$ channels (Prawitt et al. 2003; Brixel et al. 2010), what may be an important step leading to activation of voltage-dependent calcium channels in glucose stimulated insulin secretion (Henquin et al. 2009; Brixel et al. 2010). Brixel et al. (2010) hypothesize that TRPM5 may also have an additional role in the vesicle–membrane fusion process as $Trpm5$-mutant islets had still decreased insulin secretion when stimulated with arginine (Brixel et al. 2010). Although the exact mechanisms how TRPM5 activity is regulated and how it combines different types of sensory input in different cells are not known, the proposed hypothesis would help to explain how TRPM5 and WFS1 might interact or influence each other. The functional annotation of RNA-seq results also showed that WFS1 and TRPM5 might be connected over proinsulin processing and/or Ca$^{2+}$ signaling as it has been reported that the islets of $Wfs1$ knock-out mice have impaired Ca$^{2+}$ signaling (Ishihara et al. 2004).

Further studies are needed to verify the functional interaction between WFS1 and TRPM5 in the regulation of insulin secretion and how this downregulation may contribute to diabetes-like phenotype of WFS1-deficient mice. Although this study has some limitations, mainly regarding islet stimulation induction and sample size, in conclusion, mice with disrupted $Wfs1$ gene had fewer pancreatic islets and defective insulin secretion explaining their diabetes-like phenotype. RNA-sequencing of pancreatic islets showed that interestingly $Trpm5$ is downregulated in WFS1-deficient islets and the pathways related to tissue morphology, endocrine system development and function, molecular transport network are influenced.

**Conflict of Interest**

No conflicts of interest, financial or otherwise, are declared by the author(s).

**References**

Ashcroft, F. M., and P. Rorsman. 1989. Electrophysiology of the pancreatic beta-cell. Prog. Biophys. Mol. Biol. 54:87–143.
Barrett, T. G., and S. E. Bundey. 1997. Wolfram (DIDMOAD) syndrome. J. Med. Genet. 34:838–841.
Brixel, L. R., M. K. Monteilh-Zoller, C. S. Ingenbrandt, A. Fleig, R. Penner, T. Enklaar, et al. 2010. TRPM5 regulates glucose-stimulated insulin secretion. Pflugers Arch. 460:69–76.

Cheurfa, N., G. M. Brenner, A. F. Reis, D. Dubois-Laforgue, R. Roussel, J. Tichet, et al. 2011. Decreased insulin secretion and increased risk of type 2 diabetes associated with allelic variations of the WFS1 gene: the data from epidemiological study on the insulin resistance syndrome (desir) prospective study. Diabetologia 54:554–562.
Colsoul, B., A. Schraenen, K. Lemaire, R. Quintens, L. Van Lommel, A. Segal, et al. 2010. Loss of high-frequency glucose-induced Ca2+ oscillations in pancreatic islets correlates with impaired glucose tolerance in $Trpm5$-/-. Proc. Natl Acad. Sci. USA 107:5208–5213.

Cryns, K. T. A. Sivakumaran, J. M. Van den Ouweland, R. J. Pennings, C. W. Cremers, K. Flohmth, et al. 2003. Mutational spectrum of the WFS1 gene in Wolfram syndrome, nonsyndromic hearing impairment, diabetes mellitus, and psychiatric disease. Hum. Mutat. 22:275–287.

Eizirik, D. L., M. Sammeth, T. Bouckenooge, G. Bottu, G. Sisino, M. Igoillo-Esteve, et al. 2012. The human pancreatic islet transcriptome: expression of candidate genes for type 1 diabetes and the impact of pro-inflammatory cytokines. PLoS Genet. 8:e1002552.

Florez, J. C., K. A. Jablonski, J. McAteer, M. S. Sandhu, N. J. Wareham, J. Barroso, et al. 2008. Testing of diabetes-associated WFS1 polymorphisms in the Diabetes Prevention Program. Diabetologia 51:451–457.

Fonseca, S. G., M. Fukuma, K. L. Lipson, L. X. Nguyen, J. R. Allen, Y. Oka, et al. 2005. WFS1 is a novel component of the unfolded protein response and maintains homeostasis of the endoplasmic reticulum in pancreatic beta-cells. J. Biol. Chem. 280:39609–39615.

Fonseca, S. G., S. Ishigaki, C. M. Olsowski, S. Lu, K. L. Lipson, R. Ghosh, et al. 2010. Wolfram syndrome 1 gene negatively regulates ER stress signaling in rodent and human cells. J. Clin. Invest. 120:744–755.

Franks, P. W., O. Rolanndsson, S. L. Debenham, K. A. Fawcett, F. Payne, C. Dina, et al. 2008. Replication of the association between variants in WFS1 and risk of type 2 diabetes in European populations. Diabetologia 51:458–463.

Hatanaka, M., K. Tanabe, A. Yanai, Y. Ohta, M. Kondo, M. Akiyama, et al. 2011. Wolfram syndrome 1 gene (WFS1) product localizes to secretory granules and determines granule acidification in pancreatic beta-cells. Hum. Mol. Genet. 20:1274–1284.

Henquin, J. C., M. Nenquin, M. A. Ravier, and A. Szollosi. 2009. Shortcomings of current models of glucose-induced insulin secretion. Diabetes Obes. Metab. 11(Suppl 4):168–179.

van Hock, M., A. Dehghan, J. C. Witteman, C. M. van Duijn, A. G. Uitterlinden, B. A. Oostra, et al. 2008. Predicting type 2 diabetes based on polymorphisms from genome-wide association studies: a population-based study. Diabetes 57:3122–3128.

Hofmann, S., C. Philbrouk, K. D. Gerbitz, and M. F. Bauer. 2003. Wolfram syndrome: structural and functional analyses.
of mutant and wild-type wolframin, the WFS1 gene product. Hum. Mol. Genet. 12:2003–2012.
Inoue, H., Y. Tanizawa, J. Wasson, P. Behn, K. Kalidas, E. Bernal-Mizrachi, et al. 1998. A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (Wolfram syndrome). Nat. Genet. 20:143–148.
Ishihara, H., S. Takeda, A. Tamura, R. Takahashi, S. Yamaguchi, D. Takei, et al. 2004. Disruption of the WFS1 gene in mice causes progressive beta-cell loss and impaired stimulus-secretion coupling in insulin secretion. Hum. Mol. Genet. 13:1159–1170.
Karasaki, A., C. O’Hara, S. Srikanta, M. Swift, J. S. Soeldner, C. R. Kahn, et al. 1989. Genetically programmed selective islet beta-cell loss in diabetic subjects with Wolfram’s syndrome. Diabetes Care 12:135–138.
Koks, S., U. Soomets, J. L. Paya-Cano, C. Fernandes, H. Luuk, M. Plaas, et al. 2009. Wfs1 gene deletion causes growth retardation in mice and interferes with the growth hormone pathway. Physiol. Genomics 37:249–259.
Ku, G. M., H. Kim, I. W. Vaughn, M. J. Hangauer, Oh C. Myung, M. S. German, et al. 2012. Research resource: RNA-Seq reveals unique features of the pancreatic beta-cell transcriptome. Mol. Endocrinol. 26:1783–1792.
Luuk, H., S. Koks, M. Plaas, J. Hannibal, J. F. Rehfeld, and E. Vasar. 2008. Distribution of Wfs1 protein in the central nervous system of the mouse and its relation to clinical symptoms of the Wolfram syndrome. J. Comp. Neurol. 509:642–660.
Luuk, H., M. Plaas, S. Raud, J. Innos, S. Sutt, H. Lasner, et al. 2009. Wfs1-deficient mice display impaired behavioural adaptation in stressful environment. Behav. Brain Res. 198:334–345.
Minton, J. A., A. T. Hattersley, K. Owen, M. I. McCarthy, M. Walker, F. Latif, et al. 2002. Association studies of genetic variation in the WFS1 gene and type 2 diabetes in U.K. populations. Diabetes 51:1287–1290.
Moran, I., I. Akerman, M. van de Bunt, R. Xie, M. Benazra, T. Nammo, et al. 2012. Human beta cell transcriptome analysis uncovers IncRNAs that are tissue-specific, dynamically regulated, and abnormally expressed in type 2 diabetes. Cell Metab. 16:435–448.
Mortazavi, A., B. A. Williams, K. McCue, L. Schaeffer, and B. Wold. 2008. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat. Methods 5:621–628.
Mykkanen, L., S. M. Haffner, C. N. Hales, T. Ronnemaa, and M. Laakso. 1997. The relation of proinsulin, insulin, and proinsulin-to-insulin ratio to insulin sensitivity and acute insulin response in normoglycemic subjects. Diabetes 46:1990–1995.
Noormets, K., S. Koks, M. Muldmaa, L. Mauring, E. Vasar, and V. Tillmann. 2011. Sex differences in the development of diabetes in mice with deleted wolframin (Wfs1) gene. Exp. Clin. Endocrinol. Diabetes 119:271–275.
Osman, A. A., M. Saito, C. Makepeace, M. A. Permutt, P. Schlesinger, and M. Mueckler. 2003. Wolfram expression induces novel ion channel activity in endoplasmic reticulum membranes and increases intracellular calcium. J. Biol. Chem. 278:52755–52762.
Philbrook, C., E. Fritz, and H. Weiher. 2005. Expressional and functional studies of Wolframin, the gene function deficient in Wolfram syndrome, in mice and patient cells. Exp. Gerontol. 40:671–678.
Prawitt, D., M. K. Monteith-Zoller, L. Brixel, C. Spangenberg, B. Zabel, A. Fleig, et al. 2003. TRPM5 is a transient Ca2+ -activated cation channel responding to rapid changes in [Ca2+ i]i. Proc. Natl Acad. Sci. USA 100:15166–15171.
Riggs, A. C., E. Bernal-Mizrachi, M. Ohsugi, J. Wasson, S. Fatrai, C. Welling, et al. 2005. Mice conditionally lacking the Wolfram gene in pancreatic islet beta cells exhibit diabetes as a result of enhanced endoplasmic reticulum stress and apoptosis. Diabetologia 48:2313–2321.
Sandhui, M. S., M. N. Weedon, K. A. Fawcett, J. Wasson, S. L. Debenham, A. Daly, et al. 2007. Common variants in WFS1 confer risk of type 2 diabetes. Nat. Genet. 39:951–953.
Shimomura, K., J. Galvanovskis, M. Goldsworthy, A. Hugill, S. Kaizak, A. Lee, et al. 2009. Insulin secretion from beta-cells is affected by deletion of nicotinamide nucleotide transhydrogenase. Methods Enzymol. 457:451–480.
Strom, T. M., K. Hortnagel, S. Hofmann, F. Gekeler, C. Scharfe, W. R abl, et al. 1998. Diabetes insipidus, diabetes mellitus, optic atrophy and deafness (DIDMOAD) caused by mutations in a novel gene (wolframin) coding for a predicted transmembrane protein. Hum. Mol. Genet. 7:2021–2028.
Takeda, K., H. Inoue, Y. Tanizawa, Y. Matsu zuki, J. Ob a, Y. Watanabe, et al. 2001. WFS1 (Wolfram syndrome 1) gene product: predominant subcellular localization to endoplasmic reticulum in cultured cells and neuronal expression in rat brain. Hum. Mol. Genet. 10:477–484.
Takei, D., H. Ishihara, S. Yamaguchi, T. Yamada, A. Tamura, H. Katagiri, et al. 2006. WFS1 protein modulates the free Ca(2+) concentration in the endoplasmic reticulum. FEBS Lett. 580:5635–5640.
Terasmaa, A., U. Soomets, J. Ollijan, M. Punapart, M. Hansen, V. Matto, et al. 2011. Wfs1 mutation makes mice sensitive to insulin-like effect of acute valproic acid and resistant to streptozocin. J. Physiol. Biochem. 67:381–390.
Yamada, T., H. Ishihara, A. Tamura, R. Takahashi, S. Yamaguchi, D. Takei, et al. 2006. WFS1-deficiency increases endoplasmic reticulum stress, impairs cell cycle progression and triggers the apoptotic pathway specifically in pancreatic beta-cells. Hum. Mol. Genet. 15:1600–1609.